When does the dolutegravir patent expire in the EU?
Dolutegravir’s patent coverage in Europe does not expire on a single, uniform date. Availability in each EU country depends on the specific patents held for each product form (active ingredient and formulations), the jurisdiction, and whether any supplementary protection mechanisms extend protection. Because patent terms run from filing dates and differ by patent family, the exact “expiry date in the EU” can vary by country and by which patent you mean (composition of matter vs. process vs. specific formulations).
How can you find the exact EU expiry date (by country) for dolutegravir?
To pinpoint the expiry date you need to check the relevant patent and any legal extensions that apply where you plan to market or source the drug. Practically, people do this by:
- Identifying the specific dolutegravir marketing authorisation/product in the EU (the branded product matters for which national protections are asserted).
- Looking up the underlying patent family in the relevant European country patent registers.
- Checking for supplementary protection extensions that may affect time-limited exclusivity in that country (rather than a blanket EU-wide date).
If you tell me which country (e.g., Germany, France, Spain) and which dolutegravir product you mean (brand name or MA number), I can help you map what to check to get the correct expiry.
Does EU “patent expiry” differ from “market exclusivity” for dolutegravir?
Yes. Patent expiry is about the end of patent protection. Market access can still be delayed by other exclusivity or regulatory protections that are not the same thing as patents. So even if one patent expires, another patent (or protection linked to a specific formulation or use) can keep generics/biosimilars off the market in that country until it expires too.
Can generics enter the EU before every dolutegravir patent expires?
They can sometimes launch if they can design around the still-in-force patents (for example by using a different formulation or proving non-infringement/invalidity). In practice, generic entry timing in EU markets often lines up with either (a) the expiry of the last relevant patent family in that country or (b) a successful challenge that removes the barrier.
Are there challenges and litigation that affect dolutegravir expiry timing?
Where patent protection is still active, generic manufacturers may face patent disputes in national courts. Those cases can affect when products actually reach pharmacy shelves, even if the nominal expiry date is later or earlier than a market participant expected. The timeline is therefore often driven by which patents are asserted and how courts rule.
What you need to answer “dolutegravir patent expiry EU” precisely
Your question is missing the key detail that determines the answer: the country (and ideally the product/brand). Patent expiry in the EU is country- and patent-family-specific, so a single “EU expiry date” usually isn’t accurate.
Reply with:
1) which EU country you care about, and
2) the dolutegravir product/brand (or whether you mean the active ingredient generally),
and I’ll narrow the question to the relevant patent coverage and the specific expiry date to look for.